… dabigatran, dosing is even more complex: SPAF standard dose (150 mg twice daily) is reduced
to 110 mg twice daily … And, in contrast, dabigatran dose reduction is NOT recommended …

… dabigatran 110 or 150 mg twice daily (BID) vs dose-adjusted warfarin. Compared to warfarin,
dabigatran dosed at 150 mg twice daily … Dabigatran was the first DOAC that received FDA …

… with both randomized controlled trials and real-world studies. The most likely explanation …
among apixaban and dabigatran users. This finding clearly highlighted the dangers of poorly …

… our study, while dabigatran, apixaban and … dabigatran and edoxaban did not increase, and
apixaban conversely reduced the risk of GIB. Analysis of rankograms showed that dabigatran …

… In this study, we reported on real-world evidence for thromboembolic prevention from
DOAC therapy (ie, apixaban, dabigatran, edoxaban, and rivaroxaban) in comparison with no …

… In a real-world population, the rates of thromboembolism and major bleeding events
were low after elective ECV in patients using DOAC or VKA, even without routine TEE. …

… Among these studies, DOACs were assessed as a camp in 5 studies, dabigatran in 2 studies,
rivaroxaban in 3 studies, and apixaban in 2 studies (Figure 1). Detailed characteristics of …

… DOACs such as edoxaban or dabigatran since edoxaban was approved in 2015, and the
number of dabigatran users in the venous thromboembolism population was low (n=716). …

… safety of acute dabigatran treatment in patients with ischemic stroke without AF. We hypothesized
that HT rates are not increased by dabigatran … dabigatran initiation appeared to be safe …

… Our results show that Apixaban is associated with reduced GIH risk compared with Dabigatran,
Rivaroxaban and VKA, that Dabigatran is associated with reduced GIH risk compared …